Unite2Cure meets with Glenis Wilmott, MEP

Unite2Cure meeting with

From left to right: Chris Copland, Consumer Representative, National Cancer Research Institute – Pam Kearns, Director of the Cancer Research UK Clinical Trials Unit – Glenis Wilmott, MEP – Karen and Kevin Capel, Christopher’s Smile – Catherine Guinard, Public affairs Manager, CRUK

A team of Unite2Cure representatives met on Friday January 15th with MEP Glenis Wilmott, who has been actively involved in promoting changes to the Paediatric Medicines Regulation (PMR) in order to speed up the development of new drugs for kids with cancer.
Ms. Wilmott was able to provide some insight into the legislative process, but in particular, what MEPs can do to push the process forward. It is clear that what is required is a straightforward and relatively simple proposal on changes to the PMR. Framing something of this kind will be our goal during the Cancer Drug Development Forum (CDDF) congress this week in Brussels. It was also agreed that ideally a balanced set of proposals with toughening up of requirements on mechanism of action combined with some new incentives on the lines of those framed by WG2 would appear attractive.

 

Join the discussion

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: